Comparison of the therapeutic effects of pleural perfusion of NDP and cDDP in NSCLC patients with malignant pleural effusion.
- Author:
Ying-Ying CONG
1
;
Mei-Yan LIU
;
Li CAI
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; adverse effects; therapeutic use; Carcinoma, Non-Small-Cell Lung; complications; Cisplatin; administration & dosage; adverse effects; Dexamethasone; administration & dosage; adverse effects; Drainage; Female; Follow-Up Studies; Humans; Lung Neoplasms; complications; Male; Middle Aged; Neutropenia; chemically induced; Organoplatinum Compounds; administration & dosage; adverse effects; Pleural Effusion, Malignant; drug therapy; etiology; surgery; Quality of Life; Survival Rate; Vomiting; chemically induced
- From: Chinese Journal of Oncology 2010;32(6):467-469
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo compare the therapeutic effects of pleural perfusion of NDP and cDDP in non-small cell lung cancer (NSCLC) patients with malignant pleural effusion, their quality of life and toxic side effects.
METHODSSixty-eight NSCLC patients with malignant pleural effusion after chest drainage were randomly divided into two groups according to the pathological types: 34 cases in the NDP (Group A) and cDDP groups (Group B), 34 cases each. They were treated with NDP (40 mg/m(2)) and dexamethasone (10 mg) dissolved in 40 ml normal saline, or cDDP (40 mg/m(2)) and dexamethasone (10 mg) dissolved in 40 ml of normal saline, respectively, through pleural perfusion weekly for 2-4 weeks. Routine and symptomatic treatment was used in all the patients. The therapeutic effects, life quality and toxic side effects were evaluated.
RESULTSThe response rates of groups A and B were 88.23% and 61.7%, respectively, (P < 0.01). The rates of toxic side effects in groups A and B were 39.6% and 41.9%, respectively, (P > 0.05). However, the rates of gastrointestinal side effects of the two groups were 5% and 12.9%, respectively, (P < 0.05). The Karnofsky scores of group A were higher than that in group B (P < 0.05). The survival time of group A was significantly longer than that of group B.
CONCLUSIONPleural perfusion with NDP is a good treatment method with milder toxicity for patients with malignant pleural effusion caused by NSCLC.
